Andrology-Open Access
Open Access

Abstract

Persister Cells: A New Perspective on the Development of Castration-Resistant Prostate Cancer?

Yong Q Chen*

Castration-Resistant Prostate Cancer (CRPC) often has genetic alterations in the Androgen Receptor (AR) signaling pathway. Typically, CRPC drugs work by either curbing dihydrotestosterone biosynthesis or impeding AR signaling. In this mini-review, we discuss Drug-Tolerant Persister (DTP), a phenotypic state that is reversible and without genetic mutation on the AR. Persister cells may proffer a new perspective on the development of CRPC.

Published Date: 2024-03-01; Received Date: 2024-01-30